Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

IDH mutation is paradoxically associated with higher 18 F-FDOPA PET uptake in diffuse grade II and grade III gliomas.

Tytuł :
IDH mutation is paradoxically associated with higher F-FDOPA PET uptake in diffuse grade II and grade III gliomas.
Autorzy :
Verger A; Department of Nuclear Medicine, APHM, La Timone Hospital, Marseille, France.; Department of Nuclear Medicine & Nancyclotep Imaging Platform, CHRU Nancy, Lorraine University, Nancy, France.; IADI, INSERM, UMR 947, Lorraine University, Nancy, France.
Metellus P; Department of Neurosurgery, Centre Hospitalier Privé Clairval, Marseille, France.; INSERM, UMR 911, Aix-Marseille University, Marseille, France.
Sala Q; Department of Nuclear Medicine, APHM, La Timone Hospital, Marseille, France.
Colin C; INSERM, UMR 911, Aix-Marseille University, Marseille, France.
Bialecki E; Department of Neurosurgery, Centre Hospitalier Privé Clairval, Marseille, France.
Taieb D; Department of Nuclear Medicine, APHM, La Timone Hospital, Marseille, France.; CERIMED, Aix-Marseille University , Marseille, France.
Chinot O; INSERM, UMR 911, Aix-Marseille University, Marseille, France.; Department of Neuro-Oncology, APHM, La Timone Hospital, Marseille, France.
Figarella-Branger D; INSERM, UMR 911, Aix-Marseille University, Marseille, France.; Department of Anatomopathology, APHM, La Timone Hospital, Marseille, France.
Guedj E; Department of Nuclear Medicine, APHM, La Timone Hospital, Marseille, France. .; CERIMED, Aix-Marseille University , Marseille, France. .; Institut de Neurosciences de la Timone, CNRS, UMR 7289, Aix-Marseille University, Marseille, France. .; Service Central de Biophysique et Médecine Nucléaire, Hôpital de la Timone, 264 rue Saint Pierre, 13005, Marseille, France. .
Pokaż więcej
Źródło :
European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2017 Aug; Vol. 44 (8), pp. 1306-1311. Date of Electronic Publication: 2017 Mar 14.
Typ publikacji :
Journal Article
Język :
English
Imprint Name(s) :
Original Publication: Berlin : Springer-Verlag Berlin, 2002-
MeSH Terms :
Mutation*
Positron-Emission Tomography*
Dihydroxyphenylalanine/*analogs & derivatives
Glioma/*metabolism
Glioma/*pathology
Isocitrate Dehydrogenase/*genetics
Adult ; Biological Transport ; Brain Neoplasms/diagnostic imaging ; Brain Neoplasms/genetics ; Brain Neoplasms/metabolism ; Brain Neoplasms/pathology ; Dihydroxyphenylalanine/metabolism ; Female ; Glioma/diagnostic imaging ; Glioma/genetics ; Humans ; Male ; Middle Aged ; Neoplasm Grading ; Retrospective Studies
References :
Acta Neuropathol. 2016 Jun;131(6):803-20. (PMID: 27157931)
J Nucl Med. 2014 Feb;55(2):198-203. (PMID: 24379223)
Proc Natl Acad Sci U S A. 2011 Feb 22;108(8):3270-5. (PMID: 21289278)
Biometrics. 2000 Jun;56(2):451-4. (PMID: 10877303)
Anticancer Res. 2015 Sep;35(9):5117-22. (PMID: 26254416)
J Nucl Med. 2006 Jun;47(6):904-11. (PMID: 16741298)
J Neurooncol. 2012 May;107(3):527-35. (PMID: 22169956)
Acta Neuropathol. 2007 Aug;114(2):97-109. (PMID: 17618441)
Neuro Oncol. 2016 Sep;18(9):1199-208. (PMID: 27106405)
Acta Neuropathol. 2016 Oct;132(4):625-34. (PMID: 27573687)
Eur J Nucl Med Mol Imaging. 2003 Sep;30(9):1266-9. (PMID: 12856157)
Clin Nucl Med. 2015 Sep;40(9):e429-35. (PMID: 26204212)
World Neurosurg. 2016 May;89:230-9. (PMID: 26855307)
J Neurooncol. 2011 Dec;105(3):591-600. (PMID: 21643985)
Cancer Res. 2014 Jun 15;74(12):3317-31. (PMID: 24755473)
Neurology. 2010 Jun 8;74(23):1886-90. (PMID: 20427748)
Oncotarget. 2015 Oct 6;6(30):30232-8. (PMID: 26338964)
Mol Imaging. 2014;13:null. (PMID: 24825818)
Acta Neuropathol. 2013 Sep;126(3):443-51. (PMID: 23904111)
J Nucl Med. 2010 Oct;51(10 ):1532-8. (PMID: 20847166)
Mol Neurobiol. 2016 Sep 30;:null. (PMID: 27696222)
Q J Nucl Med Mol Imaging. 2014 Dec;58(4):355-65. (PMID: 25366711)
Br J Radiol. 2016 Oct;89(1066):20160476. (PMID: 27505026)
Contributed Indexing :
Keywords: 18F-FDOPA PET; Gliomas; IDH mutation; Prognosis
Substance Nomenclature :
2C598205QX (fluorodopa F 18)
63-84-3 (Dihydroxyphenylalanine)
EC 1.1.1.41 (Isocitrate Dehydrogenase)
Entry Date(s) :
Date Created: 20170316 Date Completed: 20180219 Latest Revision: 20181113
Update Code :
20210914
DOI :
10.1007/s00259-017-3668-6
PMID :
28293705
Czasopismo naukowe
Purpose: The World Health Organization Classification of Tumors of the Central Nervous System has recently been updated by the integration of diagnostic and prognostic molecular parameters, giving pivotal attention to IDH mutation as a favourable factor. Amino acid PET is increasingly used in the management of gliomas, but its prognostic value is a matter of debate. The aim of this study was to assess the relationship between IDH mutation and 18 F-FDOPA uptake on PET in newly diagnosed gliomas.
Methods: A total of 43 patients, presenting with diffuse astrocytic and oligodendroglial grade II and III gliomas, reclassified according to the 2016 WHO classification of tumours of the CNS, were retrospectively included. They had all undergone 18 F-FDOPA PET at an initial stage before surgery and histological diagnosis. 18 F-FDOPA uptake values were compared between patients with and without IDH mutation in terms of maximum standardized uptake value (SUVmax) ratios between tumour and normal contralateral brain (T/N), and between tumour and striatum (T/S).
Results: Patients with IDH mutation showed higher 18 F-FDOPA T/N SUVmax ratios (1.6 vs. 1.2) and T/S SUVmax ratios (0.9 vs. 0.6) than patients without IDH mutation (p < 0.05).
Conclusion: This study showed paradoxically higher 18 F-FDOPA uptake in diffuse grade II and III gliomas with IDH mutation. Despite evident interest in the management of gliomas, and especially in relation to posttherapy evaluation, our findings raise the question of the prognostic value of 18 F-FDOPA uptake on PET uptake in this group of patients. This may be related to differences in amino acid integration, metabolism, or cell differentiation.
Comment in: Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1411-1412. (PMID: 28470341)
Comment in: Eur J Nucl Med Mol Imaging. 2017 Dec;44(13):2328-2330. (PMID: 28803435)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies